Partner Headlines - BMY

  1. Fast Money Picks For July 7

    Benzinga
  2. Biogen, AGTC Link Up To Develop Gene Therapy

    IBD
  3. Can Hepatitis B Be A Blockbuster Bug?

    IBD
  4. Amgen Among 3 Medical Giants With Healthy Payouts

    IBD
  5. Will Bill Ackman Go After Express Scripts Next?

    GuruFocus
  6. Fast Money Picks For June 30

    Benzinga
  7. Aetna Said Close To Humana Deal; Kroger Ups Dividend

    IBD
  8. Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The ...

    GuruFocus
  9. Benzinga's Top Initiations

    Benzinga
  10. Piper Jaffray Initiates Bristol-Myers Squibb With Underperform

    Benzinga
  11. Axovant Sciences Sets 20-Year Record For Biotech IPOs

    IBD
  12. What We Don't Know About Antibiotics Could Kill Us

    FoxBusiness
  13. 2 M&A Rumors Moving The Market

    Benzinga
  14. ImmunoGen Surprises, PD-1 Drugs Under Scrutiny At ASCO

    IBD
  15. Stocks Protect Solid Gains; Bullish Setup For Zebra Technologies

    IBD
  16. Stocks Eke Out Narrow Gains; eBay Breakout Gains Traction

    IBD
  17. Options Outlook: Market Switches From 'Headline' To 'Sentiment' ...

    Benzinga
  18. 4 Stocks Rising On ASCO Cancer Drug News

    IBD
  19. Stocks Step Out To Mixed Start; Bristol Myers Rises, Wynn Fades

    IBD
  20. Bristol Dives On Cancer Drug

    IBD
  21. Stocks End On A Downer; Oil Jumps, Selling Resumes In Chipotle

    IBD
  22. Bristol Sinks On Lung Cancer Data; Merck Up On 2 Trials

    IBD
  23. Fast Money Picks For May 27

    Benzinga
  24. Merck got EU's CHMP

    IBD
  25. Puma Crashes, Roche Rises On Cancer Data News

    IBD
  26. Berenberg Initiates Bristol-Myers Squibb With Hold

    Benzinga
  27. Benzinga's Top Initiations

    Benzinga
  28. Benzinga's Top #PreMarket Losers

    Benzinga
  29. Bristol-Myers Squibb to Present Data at 2015 American Society ...

    Benzinga
  30. Making Money With Charles Payne: 05/8/15

    FoxBusiness
  31. Bayer Enters Into Collaboration With Isis For Enhancing Its Drug ...

    GuruFocus
  32. Merck's Stock Price, Dividend Yield Beating S&P 500

    IBD
  33. Bristol-Myers Squibb

    IBD
  34. Vanguard Adds to Four of Its Largest Stakes

    GuruFocus
  35. Merck Jumps, United Therapeutics Drops On Q1 Earnings

    IBD
  36. Merck Up On Q1, Januvia Report; Bristol, Pfizer Mixed

    IBD
  37. Stock Futures Mixed, Nasdaq Up; Apple, Vasco, Merck Rising

    IBD
  38. Earnings Scheduled For April 28, 2015

    Benzinga
  39. Nasdaq Leads Market Lower As Medical Stocks Tumble

    IBD
  40. 4 Drug Giants Reporting Earnings This Week

    IBD
  41. Benzinga's Weekend M&A Chatter

    Benzinga
  42. U.S. Tech, Dollar & Health Care ETFs To Watch This Week

    Benzinga
  43. Benzinga's Top Upgrades

    Benzinga
  44. Cancer Drugs Impress Again

    IBD
  45. CAR-T Therapy Stocks Hit Hard Following AACR Data

    Benzinga
  46. Bristol, Merck Cancer Drugs Strut Their Stuff

    IBD
  47. Bristol-Myers scores again

    IBD
  48. It's A Big Weekend For Biotech

    Benzinga
  49. Bristol's Opdivo Scores Again Against Lung Cancer

    IBD
  50. Bristol's Opdivo Scores Again Against Lung Cancer

    IBD
  51. Bristol-Myers Up Big After Drug Study Stopped Early

    Benzinga
  52. AstraZeneca's Onglyza Ups Risk Of Death, FDA Says

    IBD
  53. Benzinga's M&A Chatter for Monday April 13, 2015

    Benzinga
  54. Bristol-Myers Squibb Canada Announces Hepatitis C Cure Rate of ...

    Benzinga
  55. UPDATE: USDA Approves Supplimental Biologics License

    Benzinga
  56. USDA Accepts Supplemental Biologics License Application for Yervoy ...

    Benzinga
  57. Bristol Myers Reports Data Supporting Clinical Development Of ...

    Benzinga
  58. Biotech Pharmacyclics Spikes On Buyout Rumors

    IBD
  59. Bristol-Myers Squibb Launches Phase III Trial Of HIV Drug

    Benzinga
  60. Lannett Joins Big-Game Hunt For Drugmaker Acquisitions

    IBD
  61. Bristol-Myers goes for the gut

    IBD
  62. Drugmaker Mylan Takes Part In Pharma Feeding Frenzy

    IBD
  63. Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals ...

    GuruFocus
  64. Pharma M&A: Bristol-Myers, Valeant Make Deals

    IBD
  65. Morning Market Gainers

    Benzinga
  66. Evercore ISI Technical Analysis: The 'Single Best Idea'

    Benzinga
  67. Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative ...

    Benzinga
  68. Strong Dollar Weakens Views

    IBD
  69. Drugmakers Warn On Dollar

    IBD
  70. Strong Dollar Pins U.S. Corporate Earnings Outlook

    IBD
  71. Drug Firms Report Good Q4, But Outlook Cloudy

    IBD
  72. Strong Dollar Means Flabby Outlook For Some Overseas

    IBD
  73. Bristol, Pfizer, Novartis Forecasts Face FX Pressures

    IBD
  74. Tuesday Morning Movers: Microsoft, Procter & Gamble Tumble Following ...

    Benzinga
  75. UPDATE: Bristol-Meyers Squibb Posts Upbeat Q4 Results, Issues ...

    Benzinga
  76. Earnings Scheduled For January 27, 2015

    Benzinga
  77. Pharmaceuticals Sector To See High Voltage Action in 2015

    GuruFocus
  78. 3 High-Flying Health Care Stock IPOs To Watch In 2015

    IBD
  79. BRISTOL-MYERS SQUIBB

    IBD
  80. Bristol-Myers Squibb Names Caforio CEO, Andreotti To Become Chairman

    Benzinga
  81. Feeling Good With This Med Company

    GuruFocus
  82. 10 Biotech Stories You Might've Missed This Week

    Benzinga
  83. Eli Lilly Has 'Turned The Corner,' Upgraded

    IBD
  84. Celgene Outlook Is Upbeat

    IBD
  85. Celgene, Bristol-Myers Cancer Drug News Lifts Stocks

    IBD
  86. Bristol-Myers Hits 14-Year High On Cancer Drug Trial

    IBD
  87. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  88. Morning Market Gainers

    Benzinga
  89. Credit Suisse: Keep An Eye On These 6 Healthcare Stocks In 2 ...

    Benzinga
  90. What Investors Should Expect From Portola Pharmaceutical's Upcoming ...

    Benzinga
  91. Jim Cramer Advises His Viewers On Wynn Resorts And Second Sight ...

    Benzinga
  92. Bristol-Myers Squibb and California Institute for Biomedical ...

    Benzinga
  93. 5 Biotech Stocks With Big News Due In January

    IBD
  94. FDA's OKs may prescribe hits

    IBD
  95. 4 Potential Blockbuster Drugs The FDA Just Approved

    IBD
  96. Meet 5 Top Biotech Stocks Holding Up In Shaky Market

    IBD
  97. Celgene drug could gain share

    IBD
  98. Celgene's Abraxane Succeeds In Early Breast Cancer

    IBD
  99. Merck's Keytruda Might Treat Virulent Breast Cancer

    IBD
  100. US Stock Futures Edge Lower Ahead Of Federal Budget

    Benzinga
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!